Henry Schein Inc. has been closing acquisitions and investing in AI tools to bolster dental practices, signaling a trend toward innovation and expansion. However, the bio-tech firm's EPS and sales have both missed Q1 estimates, prompting fluctuations in the stock's value and performance against competitors. Several investors and firms, including Benjamin F. Edwards & Co., Metis Global Partners LLC, Amalgamated Bank, and the Swiss National Bank have been adjusting their stakes. Despite hitting a comparably rocky financial performance with reported break-even earnings for Q2 and reduction in earnings estimates for FY2025, the company appears to be undervalued by 33% according to Barrington Research. This makes it an attractive long-term value stock for investors. Notable is the cyber attack it faced in Q4, which calls into question the firm's data security measures. With HSIC's Q1 being described as a 'mixed-bag', numerous financial institutions like Barrington Research and UBS Group have revised their price targets for the company.
Henry Schein HSIC News Analytics from Mon, 16 Oct 2023 07:00:00 GMT to Sun, 12 May 2024 11:51:22 GMT -
Rating 4
- Innovation 6
- Information 5
- Rumor -1
